Article info
Research ethics
Paper
Vaccine testing for emerging infections: the case for individual randomisation
- Correspondence to Professor Nir Eyal, Department of Global Health and Population, Harvard T. H. Chan School of Public Health, FXB Building, 7th floor, 651 Huntington Ave., Boston, MA 02115, USA; neyal{at}hsph.harvard.edu
Citation
Vaccine testing for emerging infections: the case for individual randomisation
Publication history
- Received November 14, 2015
- Revised January 28, 2017
- Accepted March 6, 2017
- First published April 10, 2017.
Online issue publication
February 21, 2018
Article Versions
- Previous version (29 August 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine research
- Ethical considerations for epidemic vaccine trials
- The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola
- Delaying and withholding interventions: ethics and the stepped wedge trial
- Ebola: evaluating vaccines during epidemics
- Estimating the probability of demonstrating vaccine efficacy in the declining Ebola epidemic: a Bayesian modelling approach
- Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review
- Ebola vaccine trial results are “extremely promising,” says WHO
- Evolving pharmacovigilance requirements with novel vaccines and vaccine components
- Ebola: a game changer for vaccines, or a scare that will soon be forgotten?